A detailed history of Winton Group LTD transactions in Exelixis, Inc. stock. As of the latest transaction made, Winton Group LTD holds 268,853 shares of EXEL stock, worth $9.09 Million. This represents 0.53% of its overall portfolio holdings.

Number of Shares
268,853
Previous 44,584 503.03%
Holding current value
$9.09 Million
Previous $1 Million 596.9%
% of portfolio
0.53%
Previous 0.07%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$21.96 - $27.6 $4.92 Million - $6.19 Million
224,269 Added 503.03%
268,853 $6.98 Million
Q2 2024

Aug 09, 2024

BUY
$20.34 - $23.73 $1,545 - $1,803
76 Added 0.17%
44,584 $1 Million
Q1 2024

May 14, 2024

BUY
$20.17 - $23.93 $448,177 - $531,724
22,220 Added 99.69%
44,508 $1.06 Million
Q4 2023

Feb 12, 2024

SELL
$19.25 - $24.13 $14,341 - $17,976
-745 Reduced 3.23%
22,288 $534,000
Q3 2023

Nov 13, 2023

SELL
$19.04 - $22.74 $32,348 - $38,635
-1,699 Reduced 6.87%
23,033 $503,000
Q2 2023

Aug 14, 2023

SELL
$18.17 - $20.48 $3.5 Million - $3.94 Million
-192,453 Reduced 88.61%
24,732 $472,000
Q1 2023

May 12, 2023

BUY
$16.3 - $19.41 $559,905 - $666,733
34,350 Added 18.79%
217,185 $4.22 Million
Q4 2022

Feb 14, 2023

BUY
$14.96 - $17.39 $546,653 - $635,447
36,541 Added 24.98%
182,835 $2.93 Million
Q3 2022

Nov 10, 2022

BUY
$15.68 - $22.27 $82,367 - $116,984
5,253 Added 3.72%
146,294 $2.29 Million
Q2 2022

Aug 10, 2022

BUY
$17.44 - $23.16 $1.3 Million - $1.73 Million
74,720 Added 112.66%
141,041 $2.94 Million
Q1 2022

May 11, 2022

BUY
$17.03 - $22.67 $43,971 - $58,533
2,582 Added 4.05%
66,321 $1.5 Million
Q4 2021

Feb 10, 2022

BUY
$15.84 - $21.88 $160,886 - $222,235
10,157 Added 18.96%
63,739 $1.17 Million
Q3 2021

Oct 28, 2021

BUY
$16.3 - $21.14 $6,161 - $7,990
378 Added 0.71%
53,582 $1.13 Million
Q2 2021

Aug 10, 2021

SELL
$17.95 - $25.56 $99,532 - $141,730
-5,545 Reduced 9.44%
53,204 $969,000
Q1 2021

Jul 21, 2021

SELL
$20.53 - $25.22 $310,618 - $381,578
-15,130 Reduced 20.48%
58,749 $1.33 Million
Q4 2020

Feb 12, 2021

SELL
$18.39 - $24.8 $2.95 Million - $3.98 Million
-160,336 Reduced 68.46%
73,879 $1.48 Million
Q3 2020

Oct 30, 2020

BUY
$20.67 - $26.94 $234,852 - $306,092
11,362 Added 5.1%
234,215 $5.73 Million
Q2 2020

Aug 05, 2020

SELL
$16.46 - $27.42 $4.29 Million - $7.14 Million
-260,568 Reduced 53.9%
222,853 $5.29 Million
Q1 2020

May 11, 2020

SELL
$14.46 - $21.8 $3.04 Million - $4.58 Million
-209,990 Reduced 30.28%
483,421 $8.33 Million
Q4 2019

Feb 13, 2020

BUY
$15.15 - $18.89 $9.47 Million - $11.8 Million
625,051 Added 914.35%
693,411 $12.2 Million
Q3 2019

Nov 08, 2019

BUY
$17.68 - $22.65 $726,329 - $930,507
41,082 Added 150.6%
68,360 $1.21 Million
Q2 2019

Jul 08, 2019

BUY
$18.93 - $24.75 $309,675 - $404,885
16,359 Added 149.82%
27,278 $583,000
Q1 2019

May 13, 2019

BUY
$19.6 - $24.76 $214,012 - $270,354
10,919 New
10,919 $260,000
Q4 2018

Feb 05, 2019

SELL
$13.65 - $21.8 $186,813 - $298,354
-13,686 Closed
0 $0
Q3 2018

Nov 02, 2018

SELL
$15.87 - $22.4 $173,141 - $244,383
-10,910 Reduced 44.36%
13,686 $0
Q2 2018

Aug 20, 2018

SELL
$18.56 - $22.45 $397,889 - $481,283
-21,438 Reduced 46.57%
24,596 $0
Q1 2018

May 21, 2018

BUY
$22.15 - $31.89 $1.02 Million - $1.47 Million
46,034 New
46,034 $0

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.9B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Winton Group LTD Portfolio

Follow Winton Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Winton Group LTD with notifications on news.